EUCTR2017-004100-22-BG进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients with Multiple Sclerosis (Study OS440-3004)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 510
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and female subjects will be considered eligible for participation in the study if all the following inclusion criteria are satisfied at Visit 1 (Screening).
- •1. Subjects 18 to 65 years of age, inclusive.
- •2. An established diagnosis per McDonald Criteria (Polman et al 2011) of MS (either RR or SP course) that manifests a documented history of spasticity for at least 6 months prior to screening.
- •3. Spasticity due to MS as shown by a TNmAS-MAL score =21.
- •4. Expanded Disability Status Scale (EDSS) score =3.0.
- •5. If receiving disease-modifying medications (eg, interferons approved for MS, glatiramer acetate, natalizumab, fingolimod, or mitoxantrone), there must be no change in dose for at least 3 months prior to Visit 1 (Screening), and the subject must be willing to maintain this treatment dose for the duration of the study. If receiving AMPYRA® (dalfampridine, fampridine, 4-amino puridine), subject must be at a stable dose for at least 3 months prior
- •to Visit 1 (Screening).
- •6. Stable regimen for at least 3 months prior to Visit 2 (Baseline) for all medications and non-pharmacological therapies that are intended to alleviate spasticity.
- •a. Subjects taking medications indicated for the treatment of spasticity (eg, baclofen,benzodiazepines, cannabinoids, carisoprodol, dantrolene, tizanidine, cyclobenzaprine, any neuroleptic, ropinoprole, tolperisone, and clonidine) at Visit 1 (Screening) must wash out from these medications for at most 21 days by Visit 2 (Baseline) in order to be eligible for randomization (see Section 7.7 for washout periods for specific medications). Subjects found not to meet this criterion will be withdrawn from the study and will be considered screen failures.
- •7. Absence of infections, peripheral vascular disease, painful contractures, advanced arthritis, or other conditions that hinder evaluation of joint movement.
- •8. Creatinine clearance, as calculated by the glomerular filtration rate (GFR) using the Modification of Diet in Renal Disease Study (MDRD) formula,2 of >50 mL/minute.
- •9. Use of a medically highly effective form of birth control (see Section 7.8) during the study and for 3 months thereafter for women of child-bearing potential (including female subjects and female partners of non-sterile male subjects). Use of a medically highly effective form of birth control (see Section 7.8) during the study and for 3 months thereafter for any subject whose partner is not sterilized or post menopausal.
- •10. Willing to sign the informed consent form (ICF).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 490
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1. Any concomitant disease or disorder that has symptoms of spasticity or that may influence the subject's level of spasticity.
- •2. Inability to rate their level of spasticity or distinguish it from other MS symptoms.
- •3. Acute MS exacerbation/relapse requiring treatment or disease modifying drug dose alteration within 3 months of Visit 1 (Screening).
- •4. Use of high dose (120 mg daily) oral or intravenous methylprednisolone, or equivalent, within 3 months before Visit 1 (Screening).
- •5. Concomitant use of medications that would potentially interfere with the actions of the study medication or outcome variables.
- •6. Use of botulinum toxin A or B for spasticity within 6 months of Visit 1 (Screening).
- •7. Pregnancy, lactation, or planned pregnancy during the course of the study and for 3 months after the final study visit.
- •8. Recent history (within past 12 months) of any unstable psychiatric disease (or any yes response to questions 1 or 2 on the Columbia–Suicide Severity Rating Scale [C-SSRS] at Screening), or current signs and symptoms of significant medical disorders such as severe, progressive, or uncontrolled pulmonary, cardiac, gastrointestinal, hepatic, renal, genitourinary, hematological, endocrine, immunologic, or neurological disease.
- •9. History of epilepsy.
- •10. Current significant cognitive deficit, severe or untreated anxiety, severe or untreated depression.
- •11. Subjects with abnormal micturition that requires indwelling or intermittent catheterization or with lower urinary tract symptoms (LUTS) that result in a score >26 in the Visit 2 (Baseline) Urinary Symptom Profile – USP© (USP) questionnaire. Subjects who are proficient in selfcatheterization may be included in the study at investigator discretion.
- •12. Subject has clinically significant abnormal laboratory values, in the opinion of the investigator, at Visit 1 (Screening).
- •13. Current malignancy or history of malignancy that has not been in remission for more than 5 years, except effectively treated basal cell skin carcinoma.
- •14. Any other significant disease, disorder, or significant laboratory finding which, in the opinion of the investigator, puts the subject at risk because of participation, influences the result of the study, or affects the subject’s ability to participate.
- •15. Planned elective surgery or other procedures requiring general anesthesia during the course of the study.
- •16. History of any illicit substance abuse (eg, alcohol, cocaine) or prescription for long-acting opioids within the past 12 months (tramadol use will be allowed).
- •17. Participation in another clinical research study within 1 month of Visit 1 (Screening).
研究者
相似试验
进行中（未招募）
不适用
A study in men with low testosterone to measure the effect of testosterone solution on testosterone levels, sex drive and energy.EUCTR2012-004866-16-ITEli Lilly and Company618
招募中
不适用
A Randomized, Double-Blind, Placebo-Controlled Parallel Study with an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal MeDiseases of The genitoruinary systemKCT0001108Eli Lilly Korea50
进行中（未招募）
1 期
A study in men with low testosterone to measure the effect of testosterone solution on testosterone levels, sex drive and energy.Male hypogonadismMedDRA version: 14.1 Level: PT Classification code 10021011 Term: Hypogonadism male System Organ Class: 10014698 - Endocrine disordersEUCTR2012-004866-16-GBEli Lilly and Company715
进行中（未招募）
1 期
A study in men with low testosterone to measure the effect of testosterone solution on testosterone levels, sex drive and energy.Male hypogonadismMedDRA version: 14.1Level: PTClassification code 10021011Term: Hypogonadism maleSystem Organ Class: 10014698 - Endocrine disordersEUCTR2012-004866-16-DEEli Lilly and Company715
已完成
3 期
Randomized, db, Placebo-Controlled 18 Week Study of BI 1356 in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea DrugCTRI/2009/091/000119Boehringer Ingelheim255